### Tables

1.1 Trends in merger remedies

1.2 Distribution of mergers and remedies across broad sectors

1.2(a) The case study industries

3.1 EC remedy types, 1996–2000

3.2 An alternative classification of EC remedy types, 1991–2005

3.3 Remedy by type of competition concern

3.4 Remedies by theory of harm

5.1 NACE 21 pulp, paper and paper products

5.2 Merger interventions classified by markets in which remedies imposed

5.3 Paper production and consumption by grade, 2001: CEPI classification

5.4 Some indicators of structure and performance

5.5 Geographical distribution of production by broad product category, leading countries’ shares

5.6 European firms in the world’s top 100

5.7 Capacity utilization in the graphic paper sector

5.8 Main mergers/JV proposals by the largest firms

5.9 Leading market shares and concentration in the graphic paper sector

5.10 Leading market shares and concentration in the tissues sector

5.11 Leading ten market shares in packaging

6.1 Dimensions of market, 1994

6.2 Estimates of price elasticities for toilet tissue

6.3 Number and size distribution of sellers

6.4 Advertising spends, 1994 (£000)

6.5 Derivation of relative prices in the three segments

6.6 Imputing the own-price elasticities

6.7 The required comparisons

6.8 Theoretical mark-ups pre- and post-merger

6.9 Simulated price increases according to diversion ratio

6.10 Imputed market shares for individual private labels

6.11 Simulation results for toilet tissues
6.12 Simulation results for kitchen towels and facials 114
6.13 Actual price outcomes 115
6.14 Actual market shares 117
6.15 Market structure in 2000 (by volume) 120
6.16 The required comparisons 124
6.17 Simulated price increases 130
7.1 NACE 24.4 manufacture of pharmaceuticals, medicinal chemicals and botanical products 135
7.1 (a) Anatomical therapeutic chemical classification system 136
7.1 (b) Typical drug groups as used in the industry (for example, company reports) 136
7.2 Merger interventions classified by drug type for which remedies were imposed 137
7.3 Size of the world’s market in pharmaceuticals, 1985–2002 140
7.3 (a) The member states, the USA and Japan 141
7.4 The world’s 50 largest pharmaceutical firms, 2002 142
7.5 The world’s top selling drugs, 2002 144
7.6 Main mergers by the largest firms 145
7.7 The impact of mega-mergers on Europe’s top ten in 2002 147
7.8 US FDA approval timescale 152
7.9 Regulatory success rates for pipeline products 153
7.10 Mean number of competitor products per molecule by country 164
7.11 Importance of elasticities – market share analysis compared with basic simulation (using PCAIDS) 173
8.1 Pharmaceuticals mergers, markets and simulations 180
8.2 Market shares for selected CCR markets 185
8.3 Simulated effect of allowing merger of BM/Roche CCS businesses 187
8.4 Market shares in immediate-release analgesics in Sweden 192
8.5 Simulated effect of allowing merger and accepted remedies for PU/Monsanto in immediate-release analgesics in Sweden 193
8.6 Commercial and scientific names of main products 209
8.7 AstraZeneca: chirocaine simulations 212
8.8 Market shares in anti-virals (excluding HIV) 221
8.9 Simulated effects of unremedied GWSB merger in anti-virals (excluding HIV) 222
8.10 Market shares in topical anti-virals 223
8.11 Simulated effects of unremedied GWSB merger in topical anti-virals 224
9.1 Summary assessment of case study mergers and remedies 241